BR0315188A - Composto de cefem - Google Patents
Composto de cefemInfo
- Publication number
- BR0315188A BR0315188A BR0315188-3A BR0315188A BR0315188A BR 0315188 A BR0315188 A BR 0315188A BR 0315188 A BR0315188 A BR 0315188A BR 0315188 A BR0315188 A BR 0315188A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkyl
- formula
- amino
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"COMPOSTOS DE CEFEM". A invenção presente refere-se a um composto da fórmula [I]: onde R^ 1^ é alquila inferior, hidroxi-alquila (inferior) ou halo-alquila (inferior), e R^ 2^ é hidrogênio ou grupo protetor amino, ou R^ 1^ e R^ 2^ estão ligados entre si e formam alquileno inferior ou alquenileno inferior; R^ 3^ é hidrogênio ou alquila inferior; R^ 4^ é R^ 5^ é carboxi ou carboxi protegido; e R^ 6^ é amino ou amino protegido, ou um sal farmaceuticamente aceitável do mesmo, um processo para preparar um composto da fórmula [I], e uma composição farmacêutica compreendendo um composto da fórmula [I] em mistura com um condutor farmaceuticamente aceitável.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002952355A AU2002952355A0 (en) | 2002-10-30 | 2002-10-30 | Cephem compounds |
AU2003904813A AU2003904813A0 (en) | 2003-09-04 | Cephem Compounds | |
PCT/JP2003/013684 WO2004039814A1 (en) | 2002-10-30 | 2003-10-27 | Cephem compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0315188A true BR0315188A (pt) | 2005-09-06 |
BRPI0315188B1 BRPI0315188B1 (pt) | 2017-04-25 |
BRPI0315188B8 BRPI0315188B8 (pt) | 2021-05-25 |
Family
ID=32231625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0315188A BRPI0315188B8 (pt) | 2002-10-30 | 2003-10-27 | composto e composição farmacêutica |
Country Status (20)
Country | Link |
---|---|
US (2) | US7129232B2 (pt) |
EP (1) | EP1556389B9 (pt) |
JP (1) | JP4448821B2 (pt) |
KR (1) | KR101023035B1 (pt) |
AR (1) | AR041729A1 (pt) |
AT (1) | ATE368042T1 (pt) |
BE (1) | BE2016C002I2 (pt) |
BR (1) | BRPI0315188B8 (pt) |
CA (1) | CA2504730C (pt) |
DE (1) | DE60315178T3 (pt) |
DK (1) | DK1556389T6 (pt) |
ES (1) | ES2290498T7 (pt) |
FR (1) | FR16C0004I2 (pt) |
HK (1) | HK1086566A1 (pt) |
HU (1) | HUS1600008I1 (pt) |
LU (1) | LU92943I2 (pt) |
NL (1) | NL300793I1 (pt) |
PT (1) | PT1556389E (pt) |
TW (1) | TWI319403B (pt) |
WO (1) | WO2004039814A1 (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03010002A (es) * | 2001-05-01 | 2004-06-30 | Fujisawa Pharmaceutical Co | Compuestos de cefemo. |
ATE368042T1 (de) * | 2002-10-30 | 2007-08-15 | Astellas Pharma Inc | Cephemverbindungen |
AU2003902380A0 (en) * | 2003-05-16 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
WO2005027909A1 (en) * | 2003-09-18 | 2005-03-31 | Astellas Pharma Inc. | Cephem compounds |
JP4792974B2 (ja) * | 2003-12-25 | 2011-10-12 | 小野薬品工業株式会社 | アゼチジン環化合物およびその医薬 |
WO2007119511A1 (en) * | 2006-03-16 | 2007-10-25 | Astellas Pharma Inc. | Cephem compounds and use as antimicrobial agents |
ITFE20060029A1 (it) * | 2006-10-17 | 2008-04-18 | Gruppo Kemon Spa | Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica |
CA2935651A1 (en) | 2007-10-09 | 2009-04-16 | Gladius Pharmaceuticals Corporation | Broad spectrum beta-lactamase inhibitors |
CN105130967B (zh) * | 2011-05-13 | 2018-04-17 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
EA028342B1 (ru) | 2011-09-09 | 2017-11-30 | Мерк Шарп И Доум Корп. | Способы лечения пневмонии |
EP2628730B1 (en) * | 2012-02-16 | 2017-12-06 | Noxell Corporation | Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
CA2886402A1 (en) | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US20140274999A1 (en) | 2013-03-14 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Cephalosporin compositions and methods of manufacture |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
NZ700372A (en) * | 2013-03-15 | 2016-01-29 | Merck Sharp & Dohme | Ceftolozane antibiotic compositions |
US20140274997A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Cephalosporin pharmaceutical compositions |
EP3043797B1 (en) | 2013-09-09 | 2020-04-08 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US20160228448A1 (en) * | 2013-09-27 | 2016-08-11 | Merck Sharp & Dohme Corp. | Solid Forms of Ceftolozane |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US9120796B2 (en) | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
CR20160583A (es) | 2014-05-15 | 2017-02-23 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)urea como inhibidor de trka cinasa |
CN110204558B (zh) | 2014-08-15 | 2022-05-06 | 默沙东公司 | 头孢菌素化合物的合成 |
US10221196B2 (en) | 2014-08-15 | 2019-03-05 | Merck Sharp & Dohme Corp. | Intermediates in the synthesis of cephalosporin compounds |
US10000510B2 (en) | 2014-08-18 | 2018-06-19 | Merck Sharp & Dohme Corp. | Salt forms of ceftolozane |
WO2016095860A1 (en) * | 2014-12-18 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds |
US10059680B2 (en) | 2014-12-18 | 2018-08-28 | Merck Sharp & Dohme Corp. | Thiadiazolyl-oximinoacetic acid derivative compounds |
US20160176897A1 (en) | 2014-12-23 | 2016-06-23 | Merck Sharp & Dohme Corp. | 7-aminocephem derivative compounds |
US10214543B2 (en) | 2014-12-30 | 2019-02-26 | Merck Sharp & Dohme Corp. | Synthesis of cephalosporin compounds |
EP3313821B1 (en) * | 2015-06-29 | 2019-04-10 | Sandoz AG | Process for the preparation of carbamoylamino pyrazole derivatives |
WO2017042188A1 (en) | 2015-09-08 | 2017-03-16 | Sandoz Ag | Process for preparing ceftolozane from 7-aminocephalosporanic acid (7-aca) |
KR20180066264A (ko) | 2015-12-10 | 2018-06-18 | 나에자-알지엠 파마슈티칼스 유엘씨 | 세펨 화합물, 그의 제조 및 용도 |
EP3468968B1 (en) | 2016-06-06 | 2024-01-10 | Merck Sharp & Dohme LLC | Solid forms of ceftolozane and processes for preparing |
CN107586305A (zh) * | 2017-06-23 | 2018-01-16 | 浙江惠迪森药业有限公司 | 一种β‑内酰胺类化合物羧基及羟基保护基脱除方法 |
WO2019145784A2 (en) * | 2018-01-26 | 2019-08-01 | Legochem Biosciences, Inc. | Combination therapies for multi-drug resistant pathogens |
CN109369535A (zh) * | 2018-11-07 | 2019-02-22 | 浙江东邦药业有限公司 | 一种氨基甲酰氨基吡唑衍生化合物的制备方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR78245B (pt) * | 1980-09-12 | 1984-09-26 | Ciba Geigy Ag | |
US5194432A (en) * | 1985-11-22 | 1993-03-16 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
CA1293719C (en) * | 1986-09-22 | 1991-12-31 | Takao Takaya | Cephem compounds and processes for preparation thereof |
US5663163A (en) * | 1987-09-07 | 1997-09-02 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds and processes for preparation thereof |
US5210080A (en) * | 1987-09-07 | 1993-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
IE63094B1 (en) * | 1987-09-14 | 1995-03-22 | Fujisawa Pharmaceutical Co | Cephem compound and a process for preparation thereof |
US5173485A (en) * | 1988-03-09 | 1992-12-22 | Fujisawa Pharmaceutical Company, Ltd. | Cephem compounds |
GB8905301D0 (en) * | 1989-03-08 | 1989-04-19 | Fujisawa Pharmaceutical Co | New cephem compound and a process for preparation thereof |
US5215982A (en) * | 1989-11-10 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
KR910015587A (ko) * | 1990-02-27 | 1991-09-30 | 후지사와 토모키치로 | 세펨 화합물 |
GB9023479D0 (en) * | 1990-10-29 | 1990-12-12 | Fujisawa Pharmaceutical Co | New cephem compounds and processes for preparation thereof |
JPH09110877A (ja) | 1995-10-17 | 1997-04-28 | Katayama Seiyakushiyo:Kk | セフェム化合物、その製造法及びそれを含有する抗菌剤 |
AUPN955596A0 (en) | 1996-04-30 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
TW526202B (en) * | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
MXPA03010002A (es) * | 2001-05-01 | 2004-06-30 | Fujisawa Pharmaceutical Co | Compuestos de cefemo. |
ATE368042T1 (de) * | 2002-10-30 | 2007-08-15 | Astellas Pharma Inc | Cephemverbindungen |
AU2003902380A0 (en) * | 2003-05-16 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
WO2005027909A1 (en) * | 2003-09-18 | 2005-03-31 | Astellas Pharma Inc. | Cephem compounds |
-
2003
- 2003-10-27 AT AT03758919T patent/ATE368042T1/de active
- 2003-10-27 WO PCT/JP2003/013684 patent/WO2004039814A1/en active IP Right Grant
- 2003-10-27 KR KR1020057007538A patent/KR101023035B1/ko active Protection Beyond IP Right Term
- 2003-10-27 ES ES03758919.9T patent/ES2290498T7/es active Active
- 2003-10-27 DK DK03758919.9T patent/DK1556389T6/da active
- 2003-10-27 EP EP03758919.9A patent/EP1556389B9/en not_active Expired - Lifetime
- 2003-10-27 PT PT03758919T patent/PT1556389E/pt unknown
- 2003-10-27 CA CA2504730A patent/CA2504730C/en not_active Expired - Lifetime
- 2003-10-27 DE DE60315178.7T patent/DE60315178T3/de not_active Expired - Lifetime
- 2003-10-27 JP JP2005501847A patent/JP4448821B2/ja not_active Expired - Lifetime
- 2003-10-27 BR BRPI0315188A patent/BRPI0315188B8/pt active IP Right Grant
- 2003-10-29 TW TW092129984A patent/TWI319403B/zh active
- 2003-10-30 US US10/695,895 patent/US7129232B2/en active Active
- 2003-10-30 AR ARP030103985A patent/AR041729A1/es active IP Right Grant
-
2006
- 2006-06-07 HK HK06106532A patent/HK1086566A1/xx not_active IP Right Cessation
- 2006-10-24 US US11/585,262 patent/US20070037786A1/en not_active Abandoned
-
2016
- 2016-01-12 LU LU92943C patent/LU92943I2/xx unknown
- 2016-01-21 BE BE2016C002C patent/BE2016C002I2/fr unknown
- 2016-01-28 HU HUS1600008C patent/HUS1600008I1/hu unknown
- 2016-02-03 FR FR16C0004C patent/FR16C0004I2/fr active Active
- 2016-02-04 NL NL300793C patent/NL300793I1/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315188A (pt) | Composto de cefem | |
BR0209452A (pt) | Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto | |
BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
BR0316375A (pt) | Diazinopirimidinas | |
BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
BRPI0212346B1 (pt) | Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica. | |
BRPI0308495B8 (pt) | composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto | |
CA2383409A1 (en) | Process for preparing 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives | |
BRPI0409211A (pt) | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto | |
CA2304713A1 (en) | Biphenyl-5-alkanoic acid derivatives and use thereof | |
BR0013248A (pt) | Inibidores da adesão celular | |
AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
AU5249898A (en) | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | |
AP2001002358A0 (en) | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4- pyrrolidin-1-yl-butyl)ureido]-isothiazole-4-carboxilic acid amide and method of production. | |
BR0213139A (pt) | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica | |
HUP0302362A2 (hu) | Fejfájás, migrén, émelygés és hányás kezelésére alkalmas gyógyászati készítmény | |
BR0211118A (pt) | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal | |
BR0310032A (pt) | Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos | |
BR0313727A (pt) | Derivados de isoquinolina como inibidores de metaloproteinase da matriz | |
BRPI0406596A (pt) | Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio | |
BR0312798A (pt) | Derivados de isotiazol úteis como agentes anticancerìgenos | |
MXPA02004555A (es) | Azetidinas de [(indol-??3-il)cicloalquil]-3-substituidas para el tratamiento de padecimientos del sistema nervioso central. | |
BR0307411A (pt) | Ligantes alfa2delta para tratar zumbidos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |